Literature DB >> 26922327

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.

Claire F Friedman1, Michael A Postow2.   

Abstract

The immune system plays an essential role in the surveillance and eradication of neoplastic cells. This interaction is modulated via immunologic regulators (checkpoints). Antibodies that block the checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the programmed cell death protein 1 pathway (PD1/PD-L1) have demonstrated efficacy in a number of malignancies. However, response rates are variable, and administration of these antibodies can be associated with immune-related adverse events. Therefore, researchers are engaged in an effort to discover biomarkers that may predict response to these agents. This review focuses on potential blood and tumor-based biomarkers that have been assessed in patients treated with these checkpoint-blocking antibodies.

Entities:  

Keywords:  Biomarkers; CTLA-4; Checkpoint blockade; Immunotherapy; Ipilimumab; Melanoma; Neoantigens; Nivolumab; PD-1; PD-L1; Pembrolizumab

Mesh：

Substances：

Year:  2016        PMID： 26922327      PMCID： PMC5063308          DOI： 10.1007/s11912-016-0509-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  46 in total

1.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

2.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

3.  Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.

Authors:  Derek Ng Tang; Yu Shen; Jingjing Sun; Sijin Wen; Jedd D Wolchok; Jianda Yuan; James P Allison; Padmanee Sharma
Journal:  Cancer Immunol Res       Date:  2013-07-31       Impact factor: 11.151

4.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

5.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

6.  Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.

Authors:  S Valpione; C Martinoli; P Fava; S Mocellin; L G Campana; P Quaglino; P F Ferrucci; J Pigozzo; C Astrua; A Testori; V Chiarion-Sileni
Journal:  Eur J Cancer       Date:  2015-07-27       Impact factor: 9.162

7.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.

Authors:  Ahmad A Tarhini; Howard Edington; Lisa H Butterfield; Yan Lin; Yongli Shuai; Hussein Tawbi; Cindy Sander; Yan Yin; Matthew Holtzman; Jonas Johnson; Uma N M Rao; John M Kirkwood
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240
View more
  14 in total

Review 1.  Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.

Authors:  Amblessed E Onuma; Hongji Zhang; Hai Huang; Terence M Williams; Anne Noonan; Allan Tsung
Journal:  Gene Expr       Date:  2020-04-27

Review 2.  Circulating biomarkers predictive of tumor response to cancer immunotherapy.

Authors:  Ernest Y Lee; Rajan P Kulkarni
Journal:  Expert Rev Mol Diagn       Date:  2019-09-10       Impact factor: 5.225

3.  PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.

Authors:  Joseph M Obeid; Gulsun Erdag; Mark E Smolkin; Donna H Deacon; James W Patterson; Leiping Chen; Timothy N Bullock; Craig L Slingluff
Journal:  Oncoimmunology       Date:  2016-09-20       Impact factor: 8.110

Review 4.  PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

Authors:  Zijun Y Xu-Monette; Mingzhi Zhang; Jianyong Li; Ken H Young
Journal:  Front Immunol       Date:  2017-12-04       Impact factor: 7.561

5.  Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.

Authors:  Silvana Morello; Mariaelena Capone; Claudia Sorrentino; Diana Giannarelli; Gabriele Madonna; Domenico Mallardo; Antonio M Grimaldi; Aldo Pinto; Paolo Antonio Ascierto
Journal:  J Transl Med       Date:  2017-12-04       Impact factor: 5.531

6.  Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.

Authors:  Philip Friedlander; Karl Wassmann; Alan M Christenfeld; David Fisher; Chrisann Kyi; John M Kirkwood; Nina Bhardwaj; William K Oh
Journal:  J Immunother Cancer       Date:  2017-08-15       Impact factor: 13.751

Review 7.  Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.

Authors:  Ashley M Hopkins; Andrew Rowland; Ganessan Kichenadasse; Michael D Wiese; Howard Gurney; Ross A McKinnon; Chris S Karapetis; Michael J Sorich
Journal:  Br J Cancer       Date:  2017-08-24       Impact factor: 7.640

Review 8.  Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies.

Authors:  Dale E Johnson
Journal:  Int J Mol Sci       Date:  2018-11-21       Impact factor: 5.923

9.  A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.

Authors:  Jinkai Teo; Anja Mirenska; Meihui Tan; Yifang Lee; Janice Oh; Lewis Z Hong; Richard Wnek; Yoon-Sim Yap; Shian-Jiun Shih; Ali Asgar S Bhagat; Chih-Liang Chin; David Ag Skibinski
Journal:  Future Sci OA       Date:  2017-09-04

10.  Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma.

Authors:  Pier Francesco Ferrucci; Sara Gandini; Emilia Cocorocchio; Laura Pala; Federica Baldini; Massimo Mosconi; Gian Carlo Antonini Cappellini; Elena Albertazzi; Chiara Martinoli
Journal:  Oncotarget       Date:  2017-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.